2. Academic Validation
  3. The role of SET domain containing lysine methyltransferase 7 in tumorigenesis and development

The role of SET domain containing lysine methyltransferase 7 in tumorigenesis and development

  • Cell Cycle. 2022 Sep 13;1-7. doi: 10.1080/15384101.2022.2122257.
Shangzhen Yang 1 2,  Xi Wang 1,  Jun Bai 1,  Baojun Duan 1 3
Affiliations

Affiliations

  • 1 Department of Medical Oncology of Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
  • 2 Xi'an Medical University, Xi'an, Shaanxi, China.
  • 3 Department of Medical Oncology of Baoji Central Hospital, Baoji Central Hospital, Baoji, Shaanxi, China.
PMID: 36101480 DOI: 10.1080/15384101.2022.2122257
Abstract

SET domain containing lysine methyltransferase 7 (SETD7) belongs to the protein lysine methyltransferase family and can catalyze the monomethylation of histone H3K4, which plays a vital role in the regulation of cell cycle, cell differentiation, DNA damage response and chromatin remodeling through K/R-S/T-K (K is lysine residue) sites and the recognition of substrates mediated by SET, i-SET, and n-SET domains and electrostatic action. SETD7 also can regulate the transcription of several genes including β-catenin, Cullin l and lin-28 homolog A (LIN28A), etc. In addition, the abnormal expression of SETD7 can promote the proliferation, migration, invasion of tumor cells, predict the poor prognosis of tumor patients, and may be a potential target for tumor therapy. This paper reviews the structure of SETD7, its role in tumor genesis and development, and the current research progress of relevant targeted drugs to explore its regulatory mechanism in tumor genesis and development and the prospect of targeted therapy.

Keywords

Lysine methyltransferase; SETD7; tumor.

Figures